CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria:

1. Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurabledisease (according to IMWG diagnostic criteria.)

2. Received at least 3 prior MM treatment lines of therapy which must include aproteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38monoclonal antibody as part of a prior line of therapy, either in monotherapy or incombination.

3. Eastern Cooperative Oncology Group performance status grade of 0 or 1.

4. Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.

Exclusion Criteria:

1. Prior treatment with CAR-T cell therapy directed at any target.

2. Autologous stem cell transplant within the last 6 weeks before lymphodepletion.

3. Allogeneic stem cell transplant within 6 months before lymphodepletion.

4. Known active or prior history of CNS involvement.

5. Stroke or seizure within 6 months of signing ICF.

6. Seropositive for or history of human immunodeficiency virus.

7. Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion.

8. Hepatitis B infection.

9. Hepatitis C infection.

10. Known life-threatening allergies, hypersensitivity, or intolerance to CB-011 or itsexcipients.